Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A cancer charity has expressed its disappointment after the health regulator said a new drug to treat breast cancer did not provide "value for money".
In new draft guidance, the National Institute for Health and Clinical Excellence (Nice) recommended that the drug everolimus should not be available for widespread use on the NHS to treat a form of advanced breast cancer.
The drug, also known as afinitor, is licensed for use in post-menopausal women with HER2 negative, hormone-receptor-positive advanced breast cancer if their disease has returned following a type of hormone therapy.
Breakthrough Breast Cancer urged Nice and the manufacturers, Novartis Pharmaceuticals, to find a solution to the cost of the drug.
http://www.guardian.co.uk/society/2013/mar/21/breast-cancer-drug-value-regulator
In new draft guidance, the National Institute for Health and Clinical Excellence (Nice) recommended that the drug everolimus should not be available for widespread use on the NHS to treat a form of advanced breast cancer.
The drug, also known as afinitor, is licensed for use in post-menopausal women with HER2 negative, hormone-receptor-positive advanced breast cancer if their disease has returned following a type of hormone therapy.
Breakthrough Breast Cancer urged Nice and the manufacturers, Novartis Pharmaceuticals, to find a solution to the cost of the drug.
http://www.guardian.co.uk/society/2013/mar/21/breast-cancer-drug-value-regulator